作者: Joanne E. Murphy-Ullrich , Mark J. Suto
DOI:
关键词:
摘要: The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting activity transforming growth factor beta (TGF-β). More specifically, disclosed are useful in certain cancers (e.g. multiple myeloma, hematologic malignancies), associated with excessive TGF-β including fibrosis, dermal scarring, immune dysfunction, bone loss by conversion latent active TGF-β. A method preventing activation pathology is also provided, comprising administering an amount compounds sufficient inhibit thrombospondin 1 (TSP1), resulting reduced adverse effects such as loss, dysfunction.